



WORLD ANTI-DOPING CODE
INTERNATIONAL STANDARD

PROHIBITED LIST

2025

This List shall come into effect on 1 January 2025.



世界運動禁藥管制規範
國際標準

運動禁藥禁用 清單

2025

本清單始自 2025年1月1日生效

TABLE OF CONTENTS

Please note that the list of examples of medical conditions below is not inclusive.

SUBSTANCES & METHODS PROHIBITED AT ALL TIMES

S0 Non-approved substances	4
S1 Anabolic agents.....	5
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. male hypogonadism.	
S2 Peptide hormones, growth factors, related substances, and mimetics	7
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaemia, male hypogonadism, growth hormone deficiency.	
S3 Beta-2 agonists	9
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. asthma and other respiratory disorders.	
S4 Hormone and metabolic modulators.....	10
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. breast cancer, diabetes, infertility (female), polycystic ovarian syndrome.	
S5 Diuretics and masking agents.....	12
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. heart failure, hypertension.	
M1 – M2 – M3 Prohibited Methods	13

SUBSTANCES & METHODS PROHIBITED IN-COMPETITION

S6 Stimulants	14
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaphylaxis, attention deficit hyperactivity disorders (ADHD), cold and influenza symptoms.	
S7 Narcotics	16
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. pain, including from musculoskeletal injuries.	
S8 Cannabinoids.....	17
S9 Glucocorticoids.....	18
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. allergy, anaphylaxis, asthma, inflammatory bowel disease.	

SUBSTANCES PROHIBITED IN PARTICULAR SPORTS

P1 Beta-blockers.....	19
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. heart failure, hypertension.	

INDEX.....	20
------------	----

目錄

請注意，非下列列舉之醫療狀況，亦可能屬於禁藥範疇。

隨時禁用的物質與方法

S0 未經核可之物質	4
S1 同化性製劑	5
這些物質可能會在用於治療（例示，但不僅限於）：男性性腺功能低下藥物可能含有此類物質。	
S2 胜肽荷爾蒙、生長因子、其相關物質與相似物	7
這些物質可能會在用於治療（例示，但不僅限於）：貧血、男性性腺功能低下、生長激素缺乏症的藥物可能含有此類物質。	
S3 乙二型交感神經致效劑	9
這些物質可能會在用於治療（例示，但不僅限於）：氣喘及其他呼吸道疾病的藥物中發現。	
S4 荷爾蒙與代謝調節劑	10
這些物質可能會在用於治療（例示，但不僅限於）：乳癌、糖尿病、女性不孕、多囊性卵巢症候群的藥物可能含有此類物質。	
S5 利尿劑及干擾劑	12
這些物質可能會在用於治療（例示，但不僅限於）：心衰竭、高血壓的藥物可能含有此類物質。	
M1-M2-M3 禁用方法	13

賽內禁用的物質與方法

S6 興奮劑	14
這些物質可能會在用於治療（例示，但不僅限於）：過敏性反應、注意力不足過動症、感冒及流感症狀的藥物可能含有此類物質。	
S7 麻醉性止痛劑	16
這些物質可能會在用於治療（例示，但不僅限於）：疼痛，包含骨骼肌肉傷害的藥物中發現。	
S8 大麻素類	17
S9 糖皮質類固醇	18
這些物質可能會在用於治療（例示，但不僅限於）：過敏、過敏性反應、氣喘、發炎性腸道疾病的藥物可能含有此類物質。	

特定運動種類禁用物質

P1 乙型交感神經受體阻斷劑	19
這些物質可能會在用於治療（例示，但不僅限於）：心衰竭、高血壓的藥物可能含有此類物質。	

索引	20
-----------------	-----------

THE 2025 PROHIBITED LIST WORLD ANTI-DOPING CODE

VALID 1 JANUARY 2025

Introduction

The *Prohibited List* is a mandatory *International Standard* as part of the World Anti-Doping Program.

The *List* is updated annually following an extensive consultation process facilitated by WADA. The effective date of the *List* is 01 January 2025.

The official text of the *Prohibited List* shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail.

Below are some terms used in this *List of Prohibited Substances and Prohibited Methods*.

Prohibited In-Competition

Subject to a different period having been approved by WADA for a given sport, the *In-Competition* period shall in principle be the period commencing just before midnight (at 11:59 p.m.) on the day before a *Competition* in which the *Athlete* is scheduled to participate until the end of the *Competition* and the *Sample* collection process.

Prohibited at all times

This means that the substance or method is prohibited *In-* and *Out-of-Competition* as defined in the *Code*.

Specified and non-***Specified***

As per Article 4.2.2 of the *World Anti-Doping Code*, “for purposes of the application of Article 10, all *Prohibited Substances* shall be *Specified Substances* except as identified on the *Prohibited List*. No *Prohibited Method* shall be a *Specified Method* unless it is specifically identified as a *Specified Method* on the *Prohibited List*”. As per the comment to the article, “the *Specified Substances* and *Methods* identified in Article 4.2.2 should not in any way be considered less important or less dangerous than other doping substances or methods. Rather, they are simply substances and methods which are more likely to have been consumed or used by an *Athlete* for a purpose other than the enhancement of sport performance.”

Substances of Abuse

Pursuant to Article 4.2.3 of the *Code*, *Substances of Abuse* are substances that are identified as such because they are frequently abused in society outside of the context of sport. The following are designated *Substances of Abuse*: cocaine, diamorphine (heroin), methylenedioxymethamphetamine (MDMA/“ecstasy”), tetrahydrocannabinol (THC).

Published by:
World Anti-Doping Agency
Place Victoria, 800, rue du
Square-Victoria, bureau 1700
Montréal (Québec)
H3C 0B4 Canada

URL: www.wada-ama.org
Tel: +1 514 904 9232
Fax: +1 514 904 8650
E-mail: code@wada-ama.org

2025運動禁藥禁用清單 世界運動禁藥管制規範

2025年1月1日生效

簡介

*運動禁藥禁用清單*是世界運動禁藥管制計畫中屬強制性之國際標準。

該清單由世界運動禁藥管制組織經全面的商議程序後每年更新。清單的生效日期為西元2025年1月1日。

運動禁藥清單的正式文本應由世界運動禁藥管制組織維護，並應以英語和法語公告。如英語和法語版本間有任何出入，應以英語版本為準。

以下是本 *禁用物質* 和 *禁用方法清單* 中使用的一些專有名詞。

賽內禁用

特定比賽依世界運動禁藥管制組織的核准，有不同的 *賽內期間*。原則上，*賽內期間*係指 *運動員* 表定參賽之前一日的午夜前(即晚間11點59分)起算迄比賽與 *檢體* 採集流程結束為止。

隨時禁用

意即該物質或方法於 *規範* 中定義的 *賽內* 與 *賽外期間* 皆禁止使用。

特定與非特定

如 *世界運動禁藥管制規範* 4.2.2 條述：「因應規範第10條，除 *運動禁藥禁用清單* 特別定義外，所有禁用物質皆應視為 *特定物質*。除 *運動禁藥禁用清單* 認定之 *特定方法*，否則所有禁用方法皆應視為 *非特定方法*。」並如該條文的註釋所述：「第4.2.2條所定義之特定物質及與方法，不應以任何形式認定其相較於其他禁用物質與方法更不具重要性及危險性。相反的，這些物質與方法更常見被 *運動員* 使用於增強運動表現以外的目的。」

濫用物質

根據 *世界運動禁藥管制規範* 4.2.3 條，*濫用物質* 意指在運動賽事範疇外，那些在社會中經常性被濫用的物質。下列為標定之 *濫用物質*：cocaine (古柯鹼)、diamorphine (二乙醯嗎啡；海洛因)、methylenedioxymethamphetamine (MDMA，又稱快樂丸)、tetrahydrocannabinol (四氫大麻酚；THC)。

公布出版：

World Anti-Doping Agency
Place Victoria, 800, rue du
Square-Victoria, bureau 1700
Montréal (Québec)
H3C 0B4 Canada

URL: www.wada-ama.org
Tel: +1 514 904 9232
Fax: +1 514 904 8650
E-mail: code@wada-ama.org

S0

NON-APPROVED SUBSTANCES

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

All prohibited substances in this class are *Specified Substances*.

Any pharmacological substance which is not addressed by any of the subsequent sections of the *List* and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.

This class covers many different substances including but not limited to BPC-157, 2,4-dinitrophenol (DNP), ryanodine receptor-1-calstabin complex stabilizers [e.g. S-107, S48168 (ARM210)] and troponin activators (e.g. reldesemtiv and tirasemtiv).

S0 未經核可之物質

隨時禁用 (賽內與賽外)

所有於此分類的禁用物質皆為 *特定物質*

任何未列入 *禁用清單*且目前未經任何政府衛生主管機關核准用於人體治療 (例示：藥物仍在臨床前或臨床研發階段或許可終止、設計藥物、核准只得使用於動物之物質) 之具藥理性物質屬隨時禁用。

此分類涵蓋許多不同的物質，包含但不僅限於BPC-157, 2,4- dinitrophenol (DNP), ryanodine receptor-1-calstabin complex stabilizers [e.g. S-107, S48168 (ARM210)] and troponin activators (e.g. reldesemtiv and tirasemtiv).

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

All prohibited substances in this class are non-*Specified Substances*.

Anabolic agents are prohibited.

S1.1. ANABOLIC ANDROGENIC STEROIDS (AAS)

When administered exogenously, including but not limited to:

- 1-Androstenediol (5 α -androst-1-ene-3 β , 17 β -diol)
- 1-Androstenedione (5 α -androst-1-ene-3, 17-dione)
- 1-Androsterone (3 α -hydroxy-5 α -androst-1-ene-17-one)
- 1-Epiandrosterone (3 β -hydroxy-5 α -androst-1-ene-17-one)
- 1-Testosterone (17 β -hydroxy-5 α -androst-1-ene-3-one)
- 4-Androstenediol (androst-4-ene-3 β , 17 β -diol)
- 4-Hydroxytestosterone
- (4,17 β -dihydroxyandrost-4-en-3-one)
- 5-Androstenedione (androst-5-ene-3,17-dione)
- 7 α -Hydroxy-DHEA
- 7 β -Hydroxy-DHEA
- 7-Keto-DHEA
- 11 β -Methyl-19-nortestosterone
- 17 α -Methylepithiostanol (epistane)
- 19-Norandrostenediol (estr-4-ene-3,17-diol)
- 19-Norandrostenedione (**estr-4-ene-3,17-dione**)
- Androst-4-ene-3,11,17-trione
- (11-ketoandrostenedione, adrenosterone)
- Androstanolone (5 α -dihydrotestosterone, 17 β -hydroxy-5 α -androstan-3-one)
- Androstenediol (androst-5-ene-3 β ,17 β -diol)
- Androstenedione (androst-4-ene-3,17-dione)
- Bolasterone
- Boldenone
- Boldione (androsta-1,4-diene-3,17-dione)
- Calusterone
- Clostebol
- Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17 α -ol)
- Dehydrochlormethyltestosterone (4-chloro-17 β -hydroxy-17 α -methylandrosta-1,4-dien-3-one)
- Desoxymethyltestosterone (17 α -methyl-5 α -androst-2-en-17 β -ol and 17 α -methyl-5 α -androst-3-en-17 β -ol)
- Dimethandrolone (7 α ,11 β -Dimethyl-19-nortestosterone)
- Drostanolone
- Epiandrosterone (3 β -hydroxy-5 α -androstan-17-one)
- Epi-dihydrotestosterone (17 β -hydroxy-5 β -androstan-3-one)
- Epi-testosterone
- Ethylestrenol (19-norpregna-4-en-17 α -ol)
- Fluoxymesterone
- Formebolone
- Furazabol (17 α -methyl [1,2,5]oxadiazolo[3',4':2,3]-5 α -androstan-17 β -ol)

S1 同化性製劑

隨時禁用 (賽內與賽外)

所有於此分類的禁用物質皆為 *非特定物質*

同化性製劑皆禁止使用。

S1.1. 同化性雄性類固醇 (AAS)

當由體外補充時，包含但不僅限於：

- 1-Androstenediol (5 α -androst-1-ene-3 β , 17 β -diol)
- 1-Androstenedione (5 α -androst-1-ene-3, 17-dione)
- 1-Androsterone (3 α -hydroxy-5 α -androst-1-ene-17-one)
- 1-Epiandrosterone (3 β -hydroxy-5 α -androst-1-ene-17-one)
- 1-Testosterone (17 β -hydroxy-5 α -androst-1-ene-3-one)
- 4-Androstenediol (androst-4-ene-3 β , 17 β -diol)
- 4-Hydroxytestosterone
- (4,17 β -dihydroxyandrost-4-en-3-one)
- 5-Androstenedione (androst-5-ene-3,17-dione)
- 7 α -Hydroxy-DHEA
- 7 β -Hydroxy-DHEA
- 7-Keto-DHEA
- 11 β -Methyl-19-nortestosterone
- 17 α -Methylepithiostanol (epistane)
- 19-Norandrostenediol (estr-4-ene-3,17-diol)
- 19-Norandrostenedione (**estr-4-ene-3,17-dione**)
- Androst-4-ene-3,11,17-trione
- (11-ketoandrostenedione, adrenosterone)
- Androstanolone (5 α -dihydrotestosterone, 17 β -hydroxy-5 α -androstan-3-one)
- Androstenediol (androst-5-ene-3 β ,17 β -diol)
- Androstenedione (androst-4-ene-3,17-dione)
- Bolasterone
- Boldenone
- Boldione (androsta-1,4-diene-3,17-dione)
- Calusterone
- Clostebol
- Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17 α -ol)
- Dehydrochlormethyltestosterone (4-chloro-17 β -hydroxy-17 α -methylandrosta-1,4-dien-3-one)
- Desoxymethyltestosterone (17 α -methyl-5 α -androst-2-en-17 β -ol and 17 α -methyl-5 α -androst-3-en-17 β -ol)
- Dimethandrolone (7 α ,11 β -Dimethyl-19-nortestosterone)
- Drostanolone
- Epiandrosterone (3 β -hydroxy-5 α -androstan-17-one)
- Epi-dihydrotestosterone (17 β -hydroxy-5 β -androstan-3-one)
- Epi-testosterone
- Ethylestrenol (19-norpregna-4-en-17 α -ol)
- Fluoxymesterone
- Formebolone
- Furazabol (17 α -methyl [1,2,5]oxadiazolo[3',4':2,3]-5 α -androstan-17 β -ol)

S1

ANABOLIC AGENTS (continued)

S1.1. ANABOLIC ANDROGENIC STEROIDS (AAS) (continued)

- Gestrinone
- Mestanolone
- Mesterolone
- Metandienone (17 β -hydroxy-17 α -methylandrosta-1,4-dien-3-one)
- Metenolone
- Methandriol
- Methasterone (17 β -hydroxy-2 α ,17 α -dimethyl-5 α -androstan-3-one)
- Methyl-1-testosterone (17 β -hydroxy-17 α -methyl-5 α -androst-1-en-3-one)
- Methylclostebol
- Methyldienolone (17 β -hydroxy-17 α -methylestra-4,9-dien-3-one)
- Methylnortestosterone (17 β -hydroxy-17 α -methylestr-4-en-3-one)
- Methyltestosterone
- Metribolone (methyltrienolone, 17 β -hydroxy-17 α -methylestra-4,9,11-trien-3-one)
- Mibolerone
- Nandrolone (19-nortestosterone)
- Norboletone
- Norclostebol (4-chloro-17 β -ol-estr-4-en-3-one)
- Norethandrolone
- Oxabolone
- Oxandrolone
- Oxymesterone
- Oxymetholone
- Prasterone (dehydroepiandrosterone, DHEA, 3 β -hydroxyandrost-5-en-17-one)
- Prostanazol (17 β -[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5 α -androstane)
- Quinbolone
- Stanozolol
- Stenbolone
- Testosterone
- Tetrahydrogestrinone (17-hydroxy-18 α -homo-19-nor-17 α -pregna-4,9,11-trien-3-one)
- Tibolone
- Trenbolone (17 β -hydroxyestr-4,9,11-trien-3-one)
- Trestolone (7 α -Methyl-19-nortestosterone, MENT)

and other substances with a similar chemical structure or similar biological effect(s).

S1.2. OTHER ANABOLIC AGENTS

Including, but not limited to:

Clenbuterol, osilodrostat, ractopamine, selective androgen receptor modulators [SARMs, e.g. andarine, enobosarm (ostarine), LGD-4033 (ligandrol), RAD140, S-23 and YK-11], zeranol and zilpaterol.

S1 同化性製劑 (續)

S1.1. 同化性雄性類固醇 (AAS) 續

- Gestrinone
- Mestanolone
- Mesterolone
- Metandienone (17 β -hydroxy-17 α -methylandrosta-1,4-dien-3-one)
- Metenolone
- Methandriol
- Methasterone (17 β -hydroxy-2 α ,17 α -dimethyl-5 α -androstane-3-one)
- Methyl-1-testosterone (17 β -hydroxy-17 α -methyl-5 α -androst-1-en-3-one)
- Methylclostebol
- Methyldienolone (17 β -hydroxy-17 α -methylestra-4,9-dien-3-one)
- Methylnortestosterone (17 β -hydroxy-17 α -methylestr-4-en-3-one)
- Methyltestosterone
- Metribolone (methyltrienolone, 17 β -hydroxy-17 α -methylestra-4,9,11-trien-3-one)
- Mibolerone
- Nandrolone (19-nortestosterone)
- Norboletone
- Norclostebol (4-chloro-17 β -ol-estr-4-en-3-one)
- Norethandrolone
- Oxabolone
- Oxandrolone
- Oxymesterone
- Oxymetholone
- Prasterone (dehydroepiandrosterone, DHEA, 3 β -hydroxyandrost-5-en-17-one)
- Prostanazol (17 β -[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5 α -androstane)
- Quinbolone
- Stanazolol
- Stenbolone
- Testosterone
- Tetrahydrogestrinone (17-hydroxy-18 α -homo-19-nor-17 α -pregna-4,9,11-trien-3-one)
- Tibolone
- Trenbolone (17 β -hydroxyestr-4,9,11-trien-3-one)
- Trestolone (7 α -Methyl-19-nortestosterone, MENT)

及其他具有相似化學結構或相似生物作用的物質。

S1.2. 其他同化性製劑

包含但不僅限於：

Clenbuterol, osilodrostat, ractopamine, 選擇性雄性素受體調節劑 [SARMs, 例示：andarine、enobosarm (ostarine)、LGD-4033 (ligandrol)、RAD140、S-23和YK-11]、zeranol和 zilpaterol。

S2

PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

All prohibited substances in this class are non-*Specified Substances*.

The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited.

S2.1. ERYTHROPOIETINS (EPO) AND AGENTS AFFECTING ERYTHROPOIESIS

Including, but not limited to:

- S2.1.1 Erythropoietin receptor agonists, e.g. darbepoetins (dEPO); erythropoietins (EPO); EPO-based constructs [e.g. EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)]; EPO-mimetic agents and their constructs (e.g. CNTO-530, peginesatide).
- S2.1.2 Hypoxia-inducible factor (HIF) activating agents, e.g. cobalt; daprodustat (GSK1278863); IOX2; molidustat (BAY 85-3934); roxadustat (FG-4592); vadadustat (AKB-6548); xenon.
- S2.1.3 GATA inhibitors, e.g. K-11706.
- S2.1.4 Transforming growth factor beta (TGF- β) signalling inhibitors, e.g. luspatercept; sotatercept.
- S2.1.5 Innate repair receptor agonists, e.g. asialo EPO; carbamylated EPO (CEPO).

S2

胜肽類荷爾蒙 生長因子、其他相關 物質與相似物

隨時禁用 (賽內與賽外)

所有於此分類的禁用物質皆為 *非特定物質*

下列物質及其他具有相似化學結構或相似生物作用之物質皆禁止使用。

S2.1. 紅血球生成素(EPO)及影響紅血球生成之製劑

包括但不限於：

- S2.1.1 紅血球生成素受體致效劑，例如：darbepoetins (dEPO); erythropoietins (EPO); EPO-based constructs，[例如：EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)]；紅血球相似物及其製劑(例如：CNTO-530、peginesatide)
- S2.1.2 缺氧誘導因子 (HIF) 活化劑，例如：cobalt、daprodustat (GSK1278863)、IOX2、molidustat (BAY 85-3934)、roxadustat (FG-4592)、vadadustat (AKB-6548)、xenon。
- S2.1.3 GATA抑制劑，例如：K-11706。
- S2.1.4 轉化生長因子-β (TGF-β) 訊號傳遞抑制劑，例如：luspatercept、sotatercept。
- S2.1.5 先天修復受體致效劑，例如：asiolo EPO、carbamylated EPO (CEPO)。

S2

PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS (continued)

S2.2. PEPTIDE HORMONES AND THEIR RELEASING FACTORS

S2.2.1 Testosterone-stimulating peptides in males including, but not limited to:

- chorionic gonadotrophin (CG),
- luteinizing hormone (LH),
- gonadotrophin-releasing hormone (GnRH, gonadorelin) and its agonist analogues (e.g. buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin and triptorelin),
- kisspeptin and its agonist analogues

S2.2.2 Corticotrophins and their releasing factors, e.g. corticorelin and tetracosactide

S2.2.3 Growth hormone (GH), its analogues and fragments including, but not limited to:

- growth hormone analogues, e.g. lonapegsomatropin, somapacitan and somatogon
- growth hormone fragments, e.g. AOD-9604 and hGH 176-191

S2.2.4 Growth hormone releasing factors, including, but not limited to:

- growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin)
- growth hormone secretagogues (GHS) and their mimetics [e.g. anamorelin, capromorelin, ibutamoren (MK-677), ipamorelin, lenomorelin (ghrelin), macimorelin and tabimorelin]
- GH-releasing peptides (GHRPs) [e.g. alexamorelin, examorelin (hexarelin), GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5 and GHRP-6]

S2.3. GROWTH FACTORS AND GROWTH FACTOR MODULATORS

Including, but not limited to:

- Fibroblast growth factors (FGFs)
- Hepatocyte growth factor (HGF)
- Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues
- Mechano growth factors (MGFs)
- Platelet-derived growth factor (PDGF)
- Thymosin- β 4 and its derivatives e.g. TB-500
- Vascular endothelial growth factor (VEGF)

and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.

S2

胜肽類荷爾蒙 生長因子、其他相關 物質與相似物

(續)

S2.2 胜肽荷爾蒙及其釋放因子

S2.2.1 男性睪固酮刺激胜肽包括但不限於：

- 絨毛膜促性腺激素 (CG)
- 黃體激素 (LH)
- gonadotrophin 相關釋放荷爾蒙(GnRH, gonadorelin)促進劑與類似物
(例示：buserelin、deslorelin、gonadorelin、goserelin、histrelin、leuprorelin、nafarelin 及 triptorelin)。
- kisspeptin 及其促進劑與類似物

S2.2.2 促腎上腺皮質激素及相關釋放因子，例示：cortico-relin 和 tetracosactide

S2.2.3 生長激素 (GH)、其類似物及片段，包括但不僅限於

- 生長激素類似物，例如：lonapegsomatropin、somapacitan 和 somatrogen
- 生長激素片段，例如：AOD-9604 和 hGH 176-191

S2.2.4 生長激素釋放因子，包括但不僅限於：

- 生長素釋放素 (GHRH) 及其類似物 (例示：CJC-1293、CJC-1295、sermorelin 和 tesamorelin)
- 促生長激素分泌劑 (GHS) 及其相似物 [例如：anamorelin、capromorelin, ibutamoren (MK-677), ipamorelin、lenomorelin (ghrelin), macimorelin and tabimorelin]
- 生長激素釋放胜肽 (GHRPs) [例如：alexamorelin, examorelin (hexarelin), GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5 and GHRP-6]

S2.3 生長因子及生長調節劑

包含但不僅限於：

- 纖維母細胞生長因子 (FGFs)
- 肝細胞生長因子 (HGF)
- 類胰島素生長因子-1 (IGF-1, mecasermin) 及其類似物
- 機械生長因子 (MGFs)
- 血小板衍生生長因子 (PDGF)
- 胸腺素-β4 及其衍生物，例如：TB-500
- 血管內皮生長因子 (VEGF)

及其他影響肌肉、肌腱或韌帶蛋白之合成及/或降解、血管新生、能量利用、再生能力或纖維型態改變之生長因子或生長因子調節劑。

S3 BETA-2 AGONISTS

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

All prohibited substances in this class are *Specified Substances*.

All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited.

Including, but not limited to:

- Arformoterol
- Fenoterol
- Formoterol
- Higenamine
- Indacaterol
- Levosalbutamol
- Olodaterol
- Procaterol
- Reproterol
- Salbutamol
- Salmeterol
- Terbutaline
- Tretoquinol (trimetoquinol)
- Tulobuterol
- Vilanterol

EXCEPTIONS

- Inhaled salbutamol: maximum 1600 micrograms over 24 hours in divided doses not to exceed 600 micrograms over 8 hours starting from any dose;
- Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours in divided doses not to exceed 36 micrograms over 12 hours starting from any dose;
- Inhaled salmeterol: maximum 200 micrograms over 24 hours;
- Inhaled vilanterol: maximum 25 micrograms over 24 hours.

NOTE

The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an *Adverse Analytical Finding (AAF)* unless the *Athlete* proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above.

S3 乙二型交感神經致效劑

隨時禁用 (賽內與賽外)

所有於此分類禁用物質皆為 **特定物質**

所有選擇性和非選擇性之乙二型交感神經致效劑，包含其所有光學異構物皆禁止使用。

包含但不僅限於：

- Arformoterol
- Fenoterol
- Formoterol
- Higenamine
- Indacaterol
- Levosalbutamol
- Olodaterol
- Procaterol
- Reproterol
- Salbutamol
- Salmeterol
- Terbutaline
- Tretoquinol (trimetoquinol)
- Tulobuterol
- Vilanterol

例外

- 吸入式 salbutamol：24 小時內分次劑量之總量上限為 1600 微克，從任何劑量起算 8 小時內用量不得超過 600 微克。
- 吸入式 formoterol：24 小時內分次施用劑量 (delivered dose) 總量上限為 54 微克，從任何劑量起算 12 小時內用量不得超過 36 微克。
- 吸入式 salmeterol：24 小時內總量上限為 200 微克。
- 吸入式 vilanterol：24 小時內總量上限為 25 微克。

注意

尿液中 salbutamol 濃度超過 1000 奈克/毫升或 formoterol 濃度超過 40 奈克/毫升，係不符合治療用途，將被視為 **不利檢測報告 (AAF)**，除非選手能提出藥物動力學對照研究，證明該項異常檢測結果乃因使用上述最高劑量範圍內之治療劑量 (透過吸入途徑) 所致。

S4

HORMONE AND METABOLIC MODULATORS

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

Prohibited substances in classes S4.1 and S4.2 are *Specified Substances*. Those in classes S4.3 and S4.4 are non-*Specified Substances*.

The following hormone and metabolic modulators are prohibited.

S4.1. AROMATASE INHIBITORS

Including, but not limited to:

- 2-Androst-enol (5 α -androst-2-en-17-ol)
- 2-Androst-enone (5 α -androst-2-en-17-one)
- 3-Androst-enol (5 α -androst-3-en-17-ol)
- 3-Androst-enone (5 α -androst-3-en-17-one)
- 4-Androstene-3,6,17 trione (6-oxo)
- Aminoglutethimide
- Anastrozole
- Androsta-1,4,6-triene-3,17-dione (androstatrienedione)
- Androsta-3,5-diene-7,17-dione (arimistane)
- Exemestane
- Formestane
- Letrozole
- Testolactone

S4.2. ANTI-ESTROGENIC SUBSTANCES [ANTI-ESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)]

Including, but not limited to:

- Bazedoxifene
- Clomifene
- Cyclofenil
- Elacestrant
- Fulvestrant
- Ospemifene
- Raloxifene
- Tamoxifen
- Toremifene

S4 荷爾蒙與 代謝調節劑

隨時禁用 (賽內與賽外)

分類S4.1及S4.2之禁用物質屬 *特定物質*。

分類S4.3及S4.4者屬 *非特定物質*。

下列荷爾蒙與代謝調節劑皆禁止使用。

S4.1. 芳香環轉化酶抑制劑

包含但不僅限於：

- 2-Androstenol (5 α -androst-2-en-17-ol)
- 2-Androstenone (5 α -androst-2-en-17-one)
- 3-Androstenol (5 α -androst-3-en-17-ol)
- 3-Androstenone (5 α -androst-3-en-17-one)
- 4-Androstene-3,6,17 trione (6-oxo)
- Aminoglutethimide
- Anastrozole
- Androsta-1,4,6-triene-3,17-dione (androstatrienedione)
- Androsta-3,5-diene-7,17-dione (arimistane)
- Exemestane
- Formestane
- Letrozole
- Testolactone

S4.2. 抗雌激素物質 [抗雌激素和 選擇性雌激素受體調節劑 (SERM)]

包含但不僅限於：

- Bazedoxifene
- Clomifene
- Cyclofenil
- Elacestrant
- Fulvestrant
- Ospemifene
- Raloxifene
- Tamoxifen
- Toremifene

S4

HORMONE AND METABOLIC MODULATORS (continued)

S4.3. AGENTS PREVENTING ACTIVIN RECEPTOR IIB ACTIVATION

Including, but not limited to:

- Activin A-neutralizing antibodies
- Activin receptor IIB competitors such as:
 - Decoy activin receptors (e.g. ACE-031)
- Anti-activin receptor IIB antibodies (e.g. bimagrumab)
- Myostatin inhibitors such as:
 - Agents reducing or ablating myostatin expression
 - Myostatin-binding proteins (e.g. follistatin, myostatin propeptide)
 - Myostatin- or precursor-neutralizing antibodies (e.g. apitegromab, domagrozumab, landogrozumab, stamulumab)

S4.4. METABOLIC MODULATORS

S4.4.1

- Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR, mitochondrial open reading frame of the 12S rRNA-c (MOTS-c);
- Peroxisome proliferator-activated receptor delta (PPAR δ) agonists, e.g. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid (GW1516, GW501516) and;
- Rev-erba agonists, e.g. SR9009, SR9011

S4.4.2 Insulins and insulin-mimetics, e.g. S519, S597

S4.4.3 Meldonium

S4.4.4 Trimetazidine

S4

荷爾蒙與 代謝調節劑 (續)

S4.3. 防止活化素受體IIB活化之製劑

包含但不僅限於

- Activin A-neutralizing antibodies
- Activin receptor IIB competitors such as:
 - Decoy activin receptors (e.g. ACE-031)
- Anti-activin receptor IIB **antibodies** (e.g. bimagrumab)
- Myostatin inhibitors such as:
 - Agents reducing or ablating myostatin expression
 - Myostatin-binding proteins (e.g. follistatin, myostatin propeptide)
 - Myostatin- or precursor-neutralizing antibodies (e.g. apitegromab, domagrozumab, landogrozumab, stamulumab)

S4.4. 代謝調節劑

S4.4.1

- AMP-activated protein kinase (AMPK) 活化劑，如：AICAR, mitochondrial open reading frame of the 12S rRNA-c (MOTS-c);
- Peroxisome proliferator 活化受體delta (PPAR δ) delta 致效劑，如：2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid (GW1516、GW501516)及
- Rev-erba 致效劑，如 SR9009、SR9011。

S4.4.2 胰島素和胰島素相似物，如S519、S597。

S4.4.3 Meldonium

S4.4.4 Trimetazidine

S5 DIURETICS AND MASKING AGENTS

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

All prohibited substances in this class are *Specified Substances*.

All diuretics and masking agents, including all optical isomers, e.g. *d*- and *l*- where relevant, are prohibited.

Including, but not limited to:

- Diuretics such as:
Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide; torasemide; triamterene; xipamide;
 - Vaptans, e.g. conivaptan, mozavaptan, tolvaptan;
 - Plasma expanders by intravenous administration such as:
Albumin, dextran, hydroxyethyl starch, mannitol;
 - Desmopressin;
 - Probenecid;
- and other substances with a similar chemical structure or similar biological effect(s).



EXCEPTIONS

- Drospirenone; pamabrom; and topical ophthalmic administration of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide);
- Local administration of felypressin in dental anaesthesia.



NOTE

The detection in an *Athlete's Sample* at all times or *In-Competition*, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent (except topical ophthalmic administration of a carbonic anhydrase inhibitor or local administration of felypressin in dental anaesthesia), will be considered as an *Adverse Analytical Finding (AAF)* unless the *Athlete* has an approved *Therapeutic Use Exemption (TUE)* for that substance in addition to the one granted for the diuretic or masking agent.

S5 利尿劑及干擾劑

隨時禁用 (賽內與賽外)

所有此分類的禁用物質皆屬 *特定物質*。

所有利尿劑、干擾劑包括所有光學異構物右旋及左旋相關物質皆禁止使用。
包含但不僅限於：

• 利尿劑如：

- Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide; torasemide; triamterene; xipamide;
- Vaptans, e.g. conivaptan, mozavaptan, tolvaptan;
- Plasma expanders by intravenous administration 如:
- Albumin, dextran, hydroxyethyl starch, mannitol;
- Desmopressin;
- Probenecid;

及其他具有相似化學結構或相似生物作用之物質。

例外：

- Drospirenone ; pamabrom ; 及局部眼用方式給予 carbonic anhydrase inhibitors (如：dorzolamide, brinzolamide) ;
- 牙科麻醉時局部使用之 felypressin

注意

運動員檢體在任何時候或賽內被檢測出任何下列屬於閾值上限的物質：formoterol、salbutamol、cathine、ephedrine、methylephedrine及pseudoephedrine，並與利尿劑或干擾劑一起存在 (局部眼部給予carbonic anhydrase inhibitors或牙科麻醉時局部使用felypressin除外)，視為為不利檢測報告 (AAF)，除非該運動員持有該物質已核准的治療用途豁免 (TUE)，並同時持有利尿劑或干擾劑的治療用途豁免。

PROHIBITED METHODS

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

All prohibited methods in this class are non-*Specified* except methods in M2.2. which are *Specified Methods*.

M1. MANIPULATION OF BLOOD AND BLOOD COMPONENTS

The following are prohibited:

M1.1. The *Administration* or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system.

NOTE

Donation of blood or blood components, including by apheresis, is not prohibited when performed in a collection center accredited by the relevant regulatory authority of the country in which it operates.

M1.2. Artificially enhancing the uptake, transport or delivery of oxygen.

Including, but not limited to:

Perfluorochemicals; efaproxiral (RSR13); voxelator and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation.

M1.3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means.

M2. CHEMICAL AND PHYSICAL MANIPULATION

The following are prohibited:

M2.1. *Tampering, or Attempting to Tamper*, to alter the integrity and validity of *Samples* collected during *Doping Control*.

Including, but not limited to:

Sample substitution and/or adulteration, e.g. addition of proteases to *Sample*.

M2.2. Intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations.

M3. GENE AND CELL DOPING

The following, with the potential to enhance sport performance, are prohibited:

M3.1. The use of nucleic acids or nucleic acid analogues that may alter genome sequences and/or gene expression by any mechanism. This includes but is not limited to gene editing, gene silencing and gene transfer technologies.

M3.2. The use of normal or genetically modified cells.

禁用方法

隨時禁用 (賽內與賽外)

除禁用方法M2.2 屬 特定方法外，所有於此分類之禁用方法皆屬 非特定方法

M1. 操弄血液及血液成分

下列方法禁用：

M1.1. 將任何數量的自體、異體 (同源) 或異源血液或任何來源的紅血球產品施用或重新引入循環系統。



注意

於主管機關認可之捐血中心進行捐血或其血液成分, 包括分離血液並不在禁止之列。

M1.2. 以人為方式增強氧氣的攝取、運輸與傳送。

包含但不僅限於：

全氟化合物；efaproxiral (RSR13)；voxelotor及修飾血紅素製品，例如：含血紅素之血液代用品及微膠囊血紅素製劑，不包括吸入式之氧氣補充。

M1.3. 透過物理或化學方法對血液或血液成分進行任何形式的血管內操作下列方法禁止使用：

M2. 化學及物理操縱

下列禁用：

M2.1. 篡改或企圖篡改，以改變運動禁藥管制程序中檢體採集的完整性和有效性。

包含但不僅限於：

檢體調換及/或摻雜，如：在檢體中摻入蛋白酶。

M2.2. 每12小時內靜脈輸注及/或注射總量超過100毫升，惟因在醫院治療、手術療程或臨床診斷中接受注射者不在此限。

M3. 基因及細胞禁藥

下列潛在可提升運動表現之方法禁止使用：

M3.1. 藉由任何機轉使用核酸或核酸類似物以改變基因序列及/或改變基因表現。這包含但不僅限於基因編輯、基因靜默及基因轉移技術。

M3.2. 使用正常或基因改造細胞。

S6 STIMULANTS

PROHIBITED IN-COMPETITION

All prohibited substances in this class are *Specified Substances* except those in S6.A, which are non-*Specified Substances*.

Substances of Abuse in this section: cocaine and methylenedioxymethamphetamine (MDMA / “ecstasy”)

All stimulants, including all optical isomers, e.g. *d*- and *l*- where relevant, are prohibited.

Stimulants include:

S6.A: NON-SPECIFIED STIMULANTS

- Adrafinil
- Amfepramone
- Amfetamine
- Amfetaminil
- Amiphenazole
- Benfluorex
- Benzylpiperazine
- Bromantan
- Clobenzorex
- Cocaine
- Cropropamide
- Crotetamide
- Fencamine
- Fenetylline
- Fenfluramine
- Fenproporex
- Fonturacetam
[4-phenylpiracetam (carphedon)]
- Furfenorex
- Hydrafinil (fluorenol)
- Lisdexamfetamine
- Mefenorex
- Mephentermine
- Mesocarb
- Metamfetamine(*d*-)
- *p*-methylamfetamine
- Modafinil
- Norfenfluramine
- Phendimetrazine
- Phentermine
- Prenylamine
- Prolintane

A stimulant not expressly listed in this section is a *Specified Substance*.

S6 興奮劑

賽內禁用

除列於S6.A. 的禁用物質屬 *非特定物質*外，所有於此分類之禁用物質屬 *特定物質*

本章節之 *濫用物質*：cocaine 及 methylenedioxymethamphetamine (MDMA / 又稱“快樂丸”)

所有興奮劑，包含其所有光學異構物，例如：相關的 *右旋*及*左旋*型，皆禁止使用。

興奮劑包含：

S6.A: 非特定興奮劑

- Adrafinil
- Amfepramone
- Amfetamine
- Amfetaminil
- Amiphenazole
- Benfluorex
- Benzylpiperazine
- Bromantan
- Clobenzorex
- Cocaine
- Cropropamide
- Crotetamide
- Fencamine
- Fenetylline
- Fenfluramine
- Fenproporex
- Fonturacetam
- [4-phenylpiracetam (carphedon)]
- Furfenorex
- Hydrafinit (fluorenol)
- Lisdexamfetamine
- Mefenorex
- Mephentermine
- Mesocarb
- Metamfetamine(d-)
- p-methylamfetamine
- Modafinil
- Norfenfluramine
- Phendimetrazine
- Phentermine
- Prenylamine
- Prolintane

不在此列之興奮劑視為 *特定物質*。

S6 STIMULANTS (continued)

S6.B: SPECIFIED STIMULANTS

Including, but not limited to:

- 2-phenylpropan-1-amine (β -methylphenylethylamine, BMPEA)
- 3-Methylhexan-2-amine (1,2-dimethylpentylamine)
- 4-Fluoromethylphenidate
- 4-Methylhexan-2-amine (1,3-dimethylamylamine, 1,3 DMAA, methylhexaneamine)
- 4-Methylpentan-2-amine (1,3-dimethylbutylamine)
- 5-Methylhexan-2-amine (1,4-dimethylamylamine, 1,4-dimethylpentylamine, 1,4-DMAA)
- Benzfetamine
- Cathine**
- Cathinone and its analogues, e.g. mephedrone, methedrone, and α -pyrrolidinovalerophenone
- Dimetamfetamine (dimethylamphetamine)
- Ephedrine***
- Epinephrine**** (adrenaline)
- Etamivan
- Ethylphenidate
- Etilamfetamine
- Etilefrine
- Famprofazone
- Fenbutrazate
- Fencamfamin
- Heptaminol
- Hydroxyamfetamine (parahydroxyamphetamine)
- Isometheptene
- Levmetamfetamine
- Meclofenoxate
- Methylenedioxyamphetamine
- Methylephedrine***
- Methylnaphthidate [(\pm)-methyl-2-(naphthalen-2-yl)-2-(piperidin-2-yl)acetate]
- Methylphenidate
- Midodrine
- Nikethamide
- Norfenefrine
- Octodrine (1,5-dimethylhexylamine)
- Octopamine
- Oxilofrine (methylsynephrine)
- Pemoline
- Pentetrazol
- Phenethylamine and its derivatives
- Phenmetrazine
- Phenpromethamine
- Propylhexedrine
- Pseudoephedrine*****
- Selegiline
- Sibutramine
- Solriamfetol
- Strychnine
- Tenamfetamine (methylenedioxyamphetamine)
- Tesofensine
- Tuaminoheptane

and other substances with a similar chemical structure or similar biological effect(s).

EXCEPTIONS

- Clonidine, guanfacine;
- Imidazoline derivatives for dermatological, nasal, ophthalmic or otic use (e.g. brimonidine, clonazoline, fenoxazoline, indanazoline, naphazoline, oxymetazoline, tetrazoline, tramazoline, xylometazoline) and those stimulants included in the 2025 Monitoring Program*.

* Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2025 Monitoring Program and are not considered *Prohibited Substances*.

** Cathine (d-norpseudoephedrine) and its l-isomer: Prohibited when its concentration in urine is greater than 5 micrograms per millilitre.

*** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per millilitre.

**** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents.

***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per millilitre.

S6 興奮劑 (續)

S6.B: 特定興奮劑

包含但不僅限於：

- 2-phenylpropan-1-amine (β -methylphenylethyl-amine, BMPEA)
- 3-Methylhexan-2-amine (1,2-dimethylpentylamine)
- 4-Fluoromethylphenidate
- 4-Methylhexan-2-amine (1,3-dimethylamylamine, 1,3 DMAA, methylhexaneamine)
- 4-Methylpentan-2-amine (1,3-dimethylbutylamine)
- 5-Methylhexan-2-amine (1,4-dimethylamylamine, 1,4-dimethylpentylamine, 1,4-DMAA)
- Benzfetamine
- Cathine**
- Cathinone and its analogues, e.g. mephedrone, methedrone, and α -pyrrolidinovalerophenone
- Dimetamfetamine
- (dimethylamphetamine)
- Ephedrine***
- Epinephrine**** (adrenaline)
- Etamivan
- Ethylphenidate
- Etilamfetamine
- Etilefrine
- Famprofazone
- Fenbutrazate
- Fencamfamin
- Heptaminol
- Hydroxyamfetamine (parahydroxyamphetamine)
- Isometheptene
- Levmetamfetamine
- Meclofenoxate
- Methylenedioxyamphetamine
- Methylephedrine***
- Methylnaphthidate
- [(\pm)-methyl-2-(naphthalen-2-yl)-2-(piperidin-2-yl)acetate]
- Methylphenidate
- Midodrine
- Nikethamide
- Norfenefrine
- Octodrine (1,5-dimethylhexylamine)
- Octopamine
- Oxilofrine (methylsynephrine)
- Pemoline
- Pentetrazol
- Phenethylamine and its derivatives
- Phenmetrazine
- Phenpromethamine
- Propylhexedrine
- Pseudoephedrine*****
- Selegiline
- Sibutramine
- Solriamfetol
- Strychnine
- Tenamfetamine (methylenedioxyamphetamine)
- Tesofensine
- Tuaminoheptane

及其他具有相似化學結構或相似生物作用的物質。

例外

- Clonidine · guanfacine
- 局部皮膚、鼻腔、眼用或耳用之 imidazoline 衍生物 (如：brimonidine、clonazoline、fenoxazoline、indanazoline、naphazoline、oxymetazoline、tetryzoline、tramazoline、xylometazoline) · 及 2025 年監控計畫*所列之興奮劑。

* Bupropion、caffeine、nicotine、phenylephrine、phenylpropanolamine、pipradrol及synephrine：這些物質列入2025年監控計畫，不視為**禁用物質**。

** Cathine (d-norpseudoephedrine) 及其左旋異構物：當其於尿液中濃度高於每毫升5微克時視為禁用物質。

*** 麻黃素 (ephedrine) 及甲基麻黃素 (methylephedrine)：當任一物質於尿液中濃度高於每毫升10微克時視為禁用物質。

**** 腎上腺素 (epinephrine; adrenaline)：局部途徑授予時不屬禁用範疇，例如：鼻腔、眼用，或與局部麻醉劑併用。

***** 偽麻黃素 (pseudoephedrine)：當其於尿液中濃度高於每毫升150微克時視為禁用物質。

PROHIBITED IN-COMPETITION

All prohibited substances in this class are *Specified Substances*.

Substance of Abuse in this section: diamorphine (heroin)

The following narcotics, including all optical isomers, e.g. *d*- and *l*- where relevant, are prohibited.

- Buprenorphine
- Dextromoramide
- Diamorphine (heroin)
- Fentanyl and its derivatives
- Hydromorphone
- Methadone
- Morphine
- Nicomorphine
- Oxycodone
- Oxymorphone
- Pentazocine
- Pethidine
- Tramadol

賽內禁用

所有於此分類之禁用物質皆為 *特定物質*

本章節之 *濫用物質*：diamorphine (海洛因)

下列麻醉性止痛劑，包含其所有光學異構物，如相關的 *右旋*及*左旋*型，皆禁止使用。

- Buprenorphine
- Dextromoramide
- Diamorphine
(海洛因)
- Fentanyl and its
derivatives
- Hydromorphone
- Methadone
- Morphine
- Nicomorphine
- Oxycodone
- Oxymorphone
- Pentazocine
- Pethidine
- Tramadol

S8 CANNABINOIDS

PROHIBITED IN-COMPETITION

All prohibited substances in this class are *Specified Substances*.
Substance of Abuse in this section: tetrahydrocannabinol (THC)

All natural and synthetic cannabinoids are prohibited, e.g.

- In cannabis (hashish, marijuana) and cannabis products
- Natural and synthetic tetrahydrocannabinols (THCs)
- Synthetic cannabinoids that mimic the effects of THC

EXCEPTIONS

- Cannabidiol

S8 大麻素類

賽內禁用

所有於此分類之禁用物質皆為 *特定物質*

本節之 *濫用物質*: tetrahydrocannabinol (四氫大麻酚THC)

所有天然及合成的大麻素類皆禁止使用，例如：

- 在大麻類植物 (如：hashish、marijuana) 及製劑中的大麻素類。
- 天然及合成之四氫大麻酚 (THCs)。
- 與 THC 具相似作用的合成大麻素類。

例外：

- 大麻二酚

S9 GLUCOCORTICOIDS

PROHIBITED IN-COMPETITION

All prohibited substances in this class are *Specified Substances*.

All glucocorticoids are prohibited when administered by any injectable, oral [including oromucosal (e.g. buccal, gingival, sublingual)] or rectal route.

Including, but not limited to:

- Beclometasone
- Betamethasone
- Budesonide
- Ciclesonide
- Cortisone
- Deflazacort
- Dexamethasone
- Flunisolide
- Flucortolone
- Fluticasone
- Hydrocortisone
- Methylprednisolone
- Mometasone
- Prednisolone
- Prednisone
- Triamcinolone acetonide

NOTE

- Other routes of administration (including inhaled, and topical: dental-intracanal, dermal, intranasal, ophthalmological, otic and perianal) are not prohibited when used within the manufacturer's licensed doses and therapeutic indications.

S9 糖皮質類固醇

賽內禁用

所有於此分類之禁用物質皆為 *特定物質*

所有糖皮質類固醇皆禁止以任何注射形式、口服 [包含經口腔黏膜，(如：口頰、牙齦、舌下)]或經直腸等途徑投予使用。

包含但不僅限於：

- Beclometasone
- Betamethasone
- Budesonide
- Ciclesonide
- Cortisone
- Deflazacort
- Dexamethasone
- Flunisolide
- Fluocortolone
- Fluticasone
- Hydrocortisone
- Methylprednisolone
- Mometasone
- Prednisolone
- Prednisone
- Triamcinolone acetonide

注意

- 在製造商許可劑量及適應症範圍內使用時，其它的給予途徑 (包含吸入式及局部外用於牙髓腔、皮膚、鼻腔內、眼用、耳用及肛門周圍) 則不屬於禁用範圍。

P1 BETA-BLOCKERS

PROHIBITED IN PARTICULAR SPORTS

All prohibited substances in this class are *Specified Substances*.

Beta-blockers are prohibited *In-Competition* only, in the following sports, and also prohibited *Out-of-Competition* where indicated (*).

- Archery (WA)*
- Automobile (FIA)
- Billiards (all disciplines) (WCBS)
- Darts (WDF)
- Golf (IGF)
- Mini-Golf (WMF)
- Shooting (ISSF, IPC)*
- Underwater sports (CMAS)* in all subdisciplines of freediving, spearfishing and target shooting

*Also prohibited *Out-of-Competition*

Including, but not limited to:

- Acebutolol
- Alprenolol
- Atenolol
- Betaxolol
- Bisoprolol
- Bunolol
- Carteolol
- Carvedilol
- Celiprolol
- Esmolol
- Labetalol
- Metipranolol
- Metoprolol
- Nadolol
- Nebivolol
- Oxprenolol
- Pindolol
- Propranolol
- Sotalol
- Timolol

特定運動種類禁用

所有於此分類之禁用物質皆為 *特定物質*

乙型交感神經受體阻斷劑於下列運動種類僅在賽內禁用，另有註明 (*) 者，在賽外亦禁止使用。

- 射箭 (WA) *
- 汽車賽車 (FIA)
- 撞球 (包含所有項目) (WCBS)
- 飛鏢 (WDF)
- 高爾夫 (IGF)
- 迷你高爾夫 (WMF)
- 射擊 (ISSF, IPC) *
- 水中運動 (CMAS) * 在自由潛水、水中狩獵和水中目標射擊所有次分項。

*於賽外亦禁止使用。

包含但不僅限於：

- | | | | |
|--------------|--------------|----------------|---------------|
| • Acebutolol | • Bunolol | • Labetalol | • Oxprenolol |
| • Alprenolol | • Carteolol | • Metipranolol | • Pindolol |
| • Atenolol | • Carvedilol | • Metoprolol | • Propranolol |
| • Betaxolol | • Celiprolol | • Nadolol | • Sotalol |
| • Bisoprolol | • Esmolol | • Nebivolol | • Timolol |

INDEX 索引

- (±)-Methyl-2-(naphthalen-2-yl)-2-(piperidin-2-yl)acetate, 15
- 1-Androstenediol, 5
- 1-Androstenedione, 5
- 1-Androsterone, 5
- 1-Epiandrosterone, 5
- 1-Testosterone, 5
- 1,2-Dimethylpentylamine, 15
- [1,2]Oxazolo[4',5':2,3]pregna-4-en-20-yn-17 α -ol, 5
- 1,3-Dimethylamylamine (1,3 DMAA), 15
- 1,3-Dimethylbutylamine, 15
- 1,4-Dimethylamylamine (1,4-DMAA), 15
- 1,4-Dimethylpentylamine, 15
- 1,5- Dimethyl-hexylamine, 15
- 2-Androstenol, 10
- 2-Androstenone, 10
- 2-Phenylpropan-1-amine, 15
- 2,4-Dinitrophenol (DNP), 4
- 3 α -Hydroxy-5 α -androst-1-ene-17-one, 5
- 3 β -Hydroxy-5 α -androst-1-ene-17-one, 5
- 3 β -Hydroxy-5 α -androstan-17-one, 5
- 3 β -Hydroxyandrost-5-en-17-one, 6
- 2-Androstenol, 10
- 3-Androstenone, 10
- 3-Methylhexan-2-amine, 15
- 3-Androstene-3,6,17 trione, 10
- 4-Androstenediol, 5
- 4-Chloro-17 β -hydroxy-17 α -methylandrosta-1,4-dien-3-one, 5
- 4-Chloro-17 β -ol-estr-4-en-3-one, 6
- 4-Fluoromethylphenidate, 15
- 4-Hydroxytestosterone, 5
- 4-Methylhexan-2-amine, 15
- 4-Methylpentan-2-amine, 15
- 4-Phenylpiracetam, 14
- 4,17 β -Dihydroxyandrost-4-en-3-one, 5
- 5 α -Androst-1-ene-3, 17-dione, 5
- 5 α -Androst-1-ene-3 β , 17 β -diol, 5
- 5 α -Androst-2-en-17-ol, 10
- 5 α -Androst-2-en-17-one, 10
- 5 α -Androst-3-en-17-ol, 10
- 5 α -Androst-3-en-17-one, 10
- 5 α -Dihydrotestosterone, 5
- 4-Androstenedione, 5
- 5-Methylhexan-2-amine, 15
- 5-Oxo, 10
- 7 α -Hydroxy-DHEA, 5
- 7 α ,11 β -Dimethyl-19-nortestosterone, 5
- 7 α -Methyl-19-nortestosterone, 6
- 7 β -Hydroxy-DHEA, 5
- 5-Keto-DHEA, 5
- 11 β -Methyl-19-nortestosterone, 5
- 11-Ketoandrostenedione, 5
- 17 α -Methyl [1,2,5]oxadiazolo[3',4':2,3]-5 α -androstan-17 β -ol, 5
- 17 α -Methyl-5 α -androst-2-en-17 β -ol, 5
- 17 α -Methyl-5 α -androst-3-en-17 β -ol, 5
- 17 α -Methylepithiostanol, 5
- 17 β -Hydroxy-2 α ,17 α -dimethyl-5 α -androstan-3-one, 6
- 17 β -Hydroxy-5 α -androst-1-en-3-one, 5
- 17 β -Hydroxy-5 α -androstan-3-one, 5
- 17 β -Hydroxy-5 β -androstan-3-one, 5
- 17 β -hydroxy-17 α -methyl-5 α -androst-1-en-3-one, 6
- 17 β -Hydroxy-17 α -methylandrosta-1,4-dien-3-one, 6
- 17 β -Hydroxy-17 α -methylestr-4-en-3-one, 6
- 17 β -Hydroxy-17 α -methylestra-4,9-dien-3-one, 6
- 17 β -Hydroxy-17 α -methylestra-4,9,11-trien-3-one, 6
- 17 β -Hydroxyestr-4,9,11-trien-3-one, 6
- 17 β -[(Tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5 α -androstan-6-one, 6
- 17-Hydroxy-18 α -homo-19-nor-17 α -pregna-4,9,11-trien-3-one, 6
- 19-Norandrostenediol, 5
- 19-Norandrostenedione, 5
- 19-Norpregna-4-en-17 α -ol, 5
- 19-Nortestosterone, 6
- α -Pyrrolidinovalerophenone, 15
- β -Methylphenylethylamine, 15
- ## A
- ACE-031, 11
- Acebutolol, 19
- Acetazolamide, 12
- Activators of the AMP-activated protein kinase (AMPK), 11
- Activin A-neutralizing antibodies, 11
- Activin receptor IIB competitors, 11
- Adrafinil, 14
- Adrenaline, 15
- Adrenosterone, 5
- AICAR, 11
- Albumin, 12
- Alexamorelin, 8
- Alprenolol, 19
- Amfepramone, 14
- Amfetamine, 14
- Amfetaminil, 14
- Amiloride, 12
- Aminoglutethimide, 10
- Amiphenazole, 14
- AMP-activated protein kinase (AMPK), 11
- Anamorelin, 8
- Anastrozole, 10
- Andarine, 6
- Androst-4-ene-3 β ,17 β -diol, 5
- Androst-4-ene-3,11,17- trione, 5
- Androst-4-ene-3,17-dione, 5
- Androst-5-ene-3 β ,17 β -diol, 5
- Androst-5-ene-3,17-dione, 5
- Androsta-1,4,6-triene-3,17-dione, 10
- Androsta-1,4-diene-3,17-dione, 5
- Androsta-3,5-diene-7,17-dione, 10
- Androstanolone, 5
- Androstatrienedione, 10
- Androstenediol, 5
- Androstenedione, 5
- Anti-activin receptor IIB antibodies, 11
- AOD-9604, 8
- Apheresis, 13
- Apitegomab, 11
- Arformoterol, 9
- Arimistane, 10
- ARM210, 4
- Asialo EPO, 7
- Atenolol, 19
- ## B
- Bazedoxifene, 10
- Beclometasone, 18
- Bendroflumethiazide, 12
- Benfluorex, 14
- Benzfetamine, 15
- Benzylpiperazine, 14
- Betamethasone, 18
- Betaxolol, 19
- Bimagrumab, 11
- Bisoprolol, 19
- Blood, 13
- Blood (autologous), 13
- Blood (components), 13
- Blood (heterologous), 13
- Blood (homologous), 13
- Blood manipulation, 13
- BMPEA, 15
- Bolasterone, 5

INDEX 索引

- Boldenone, 5
Boldione, 5
BPC-157, 4
Brimonidine, 15
Brinzolamide, 12
Bromantan, 14
Budesonide, 18
Bumetanide, 12
Bunolol, 19
Buprenorphine, 16
Bupropion, 15
Buserelin, 8
- C**
- Caffeine, 15
Calusterone, 5
Cannabidiol, 17
Cannabis, 17
Canrenone, 12
Capromorelin, 8
Carbamylated EPO (CEPO), 7
Carpheon, 14
Carteolol, 19
Carvedilol, 19
Cathine, 12, 15
Cathinone, 15
Celiprolol, 19
Cell (doping), 13
Cell (genetically modified), 13
Cell (normal), 13
Cell (red blood), 13
Chlorothiazide, 12
Chlortalidone, 12
Chorionic Gonadotrophin (CG), 8
Ciclesonide, 18
CJC-1293, 8
CJC-1295, 8
Clenbuterol, 6
Clobenzorex, 14
Clomifene, 10
Clonazoline, 15
Clonidine, 15
Clostebol, 5
CNTO-530, 7
Cobalt, 7
Cocaine, 14
Conivaptan, 12
Corticotropin, 8
Corticotrophins, 8
Cortisone, 18
- Cropropamide, 14
Crotetamide, 14
Cyclofenil, 10
- D**
- Danazol, 5
Daprodustat, 7
Darbepoetins (dEPO), 7
Deflazacort, 18
Dehydrochlormethyltestosterone, 5
Dehydroepiandrosterone (DHEA), 6
Deslorelin, 8
Desmopressin, 12
Desoxymethyltestosterone, 5
Dexamethasone, 18
Dextran, 12
Dextromoramide, 16
Diamorphine, 16
Dimetamfetamine, 15
Dimethandrolone, 5
Dimethylamphetamine, 15
Domagrozumab, 11
Dorzolamide, 12
Drospirenone, 12
Drostanolone, 5
- E**
- Ecstasy, 14
Efaxproxiral (RSR13), 13
Elacestrant, 10
Enobosarm, 6
Ephedrine, 12, 15
Epiandrosterone, 5
Epi-dihydrotestosterone, 5
Epinephrine, 15
Epistane, 5
Epitestosterone, 5
EPO-based constructs, 7
EPO-Fc, 7
EPO-mimetic agents, 7
Erythropoietin receptor agonists, 7
Erythropoietins (EPO), 7
Esmolol, 19
Estr-4-ene-3,17-diol, 5
Estr-4-ene-3,17-dione, 5
Etacrynic acid, 12
Etamivan, 15
Ethylestrenol, 5
Ethylphenidate, 15
Etilamfetamine, 15
- Etilefrine, 15
Examorelin, 8
Exemestane, 10
- F**
- Famprofazone, 15
Felypressin, 12
Fenbutrazate, 15
Fencamfamin, 15
Fencamine, 14
Fenetylline, 14
Fenfluramine, 14
Fenoterol, 9
Fenoxazoline, 15
Fenproporex, 14
Fentanyl, 16
Fibroblast growth factors (FGFs), 8
Flunisolide, 18
Fluocortolone, 18
Fluorenol, 14
Fluoxymesterone, 5
Fluticasone, 18
Follistatin, 11
Fonturacetam, 14
Formebolone, 5
Formestane, 10
Formoterol, 9, 12
Fulvestrant, 10
Furazabol, 5
Furfenorex, 14
Furosemide, 12
- G**
- GATA inhibitors, 7
Gene doping, 13
Gene editing, 13
Gene silencing, 13
Gene transfer, 13
Gestrinone, 6
Ghrelin, 8
GH-releasing peptides (GHRPs), 8
Gonadorelin, 8
Gonadotrophin-releasing hormone (GnRH), 8
Goserelin, 8
Growth hormone (GH), 8
Growth hormone secretagogues (GHS), 8
Guanfacine, 15
GW1516, 11
GW501516, 11

INDEX 索引

H

Haemoglobin (products), 13
Haemoglobin (based blood substitutes), 13
Haemoglobin (microencapsulated products), 13
Hashish, 17
Hepatocyte growth factor (HGF), 8
Heptaminol, 15
Heroin, 16
Hexarelin, 8
hGH 176-191, 8
Higenamine, 9
Histrelin, 8
Hydrafnil, 14
Hydrochlorothiazide, 12
Hydrocortisone, 18
Hydromorphone, 16
Hydroxyamfetamine, 15
Hydroxyethyl starch, 12
Hypoxia-inducible factor (HIF) activating agents, 7

I

Ibutamoren, 8
Imidazoline, 15
Indacaterol, 9
Indanazoline, 15
Indapamide, 12
Infusions, 13
Injections (>100 mL), 13
Innate repair receptor agonists, 7
Insulin-like growth factor-1 (IGF-1), 8
Insulin-mimetics, 11
Insulins, 11
Intravenous infusions/injections, 13
IOX2, 7
Ipamorelin, 8
Isometheptene, 15

K

K-11706, 7
Kisspeptin, 8

L

Labetalol, 19
Landogrozumab, 11
Lenomorelin, 8
Letrozole, 10
Leuprorelin, 8
Levmetamfetamine, 15

Levosalbutamol, 9
LGD-4033, 6
Ligandrol, 6
Lisdexamfetamine, 14
Lonapegsomatropin, 8
Luspatercept, 7
Luteinizing hormone (LH), 8

M

Macimorelin, 8
Mannitol, 12
Marijuana, 17
Mecasermin, 8
Mechano growth factors (MGFs), 8
Meclofenoxate, 15
Mefenorex, 14
Meldonium, 11
MENT, 6
Mephedrone, 15
Mephentermine, 14
Mesocarb, 14
Mestanolone, 6
Mesterolone, 6
Metamfetamine(*d*-), 14
Metandienone, 6
Metenolone, 6
Methadone, 16
Methandriol, 6
Methasterone, 6
Methedrone, 15
Methoxy polyethylene glycol-epoetin beta (CERA), 7
Methyl-1-testosterone, 6
Methylclostebol, 6
Methyldienolone, 6
Methylenedioxymphetamine, 15
Methylenedioxymethamphetamine, 15
Methylephedrine, 12, 15
Methylhexaneamine, 15
Methylnaphtidate, 15
Methylnortestosterone, 6
Methylphenidate, 15
Methylprednisolone, 18
Methylsynephrine, 15
Methyltestosterone, 6
Methyltrienolone, 6
Metipranolol, 19
Metolazone, 12
Metoprolol, 19
Metribolone, 6

Mibolerone, 6
Midodrine, 15
Mitochondrial open reading frame of the 12S rRNA-c, 11
MK-677, 8
Modafinil, 14
Molidustat, 7
Mometasone, 18
Morphine, 16
MOTS-c, 11
Mozavaptan, 12
Myostatin inhibitors, 11
Myostatin precursor-neutralizing antibodies, 11
Myostatin propeptide, 11
Myostatin-binding proteins, 11
Myostatin-neutralizing antibodies, 11

N

Nadolol, 19
Nafarelin, 8
Nandrolone, 6
Naphazoline, 15
Nebivolol, 19
Nicomorphine, 16
Nicotine, 15
Nikethamide, 15
Norboletone, 6
Norclostebol, 6
Norethandrolone, 6
Norfenefrine, 15
Norfenfluramine, 14
Nucleic acids, 13
Nucleic acid analogues, 13

O

Octodrine, 15
Octopamine, 15
Olodaterol, 9
Osilodrostat, 6
Ospemifene, 10
Ostarine, 6
Oxabolone, 6
Oxandrolone, 6
Oxilofrine, 15
Oxprenolol, 19
Oxycodone, 16
Oxymesterone, 6
Oxymetazoline, 15
Oxymetholone, 6
Oxymorphone, 16

INDEX 索引

P

Pamabrom, 12
Parahydroxyamphetamine, 15
Peginesatide, 7
Pemoline, 15
Pentazocine, 16
Pentetrazol, 15
Perfluorochemicals, 13
Peroxisome proliferator activated receptor delta agonists, 11
Pethidine, 16
Phendimetrazine, 14
Phenethylamine, 15
Phenmetrazine, 15
Phenpromethamine, 15
Phentermine, 14
Phenylephrine, 15
Phenylpropanolamine, 15
Pindolol, 19
Pipradrol, 15
Plasma expanders, 12
Platelet-derived growth factor (PDGF), 8
p-methylamphetamine, 14
Pralmorelin, 8
Prasterone, 6
Prednisolone, 18
Prednisone, 18
Prenylamine, 14
Probenecid, 12
Procaterol, 9
Prolintane, 14
Propranolol, 19
Propylhexedrine, 15
Prostanozol, 6
Proteases, 13
Pseudoephedrine, 12, 15

Q

Quinbolone, 6

R

RAD140, 6
Ractopamine, 6
Raloxifene, 10
Reldesemtiv, 4
Reproterol, 9

Rev-erba agonists, 11
Roxadustat, 7
Ryanodine receptor-1-calstabin complex stabilizers, 4

S

S-107, 4
S-23, 6
S48168, 4
S519, 11
S597, 11
Salbutamol, 9, 12
Salmeterol, 9
Selective androgen receptor modulators (SARMs), 6
Selegiline, 15
Sermorelin, 8
Sibutramine, 15
Solriamfetol, 15
Somapacitan, 8
Somatrogon, 8
Sotalol, 19
Sotatercept, 7
Spironolactone, 12
SR9009, 11
SR9011, 11
Stamulumab, 11
Stanozolol, 6
Stenbolone, 6
Strychnine, 15
Synephrine, 15

T

Tabimorelin, 8
Tamoxifen, 10
Tampering, 13
TB-500, 8
Tenamfetamine, 15
Terbutaline, 9
Tesamorelin, 8
Tesofensine, 15
Testolactone, 10
Testosterone, 6
Testosterone-stimulating peptides 8
Tetracosactide, 8
Tetrahydrocannabinols, 17

Tetrahydrogestrinone, 6
Tetryzoline, 15
Thiazides, 12
Thymosin- β 4, 8
Tibolone, 6
Timolol, 19
Tirasemtiv, 4
Tolvaptan, 12
Torasemide, 12
Toremifene, 10
Tramadol, 16
Tramazoline, 15
Transforming growth factor beta (TGF- β) signalling inhibitors, 7
Trenbolone, 6
Trestolone, 6
Tretroquinol, 9
Triamcinolone acetonide, 18
Triamterene, 12
Trimetazidine, 11
Trimetoquinol, 9
Triptorelin, 8
Troponin activators, 4
Tuaminoheptane, 15
Tulobuterol, 9

V

Vadadustat (AKB-6548), 7
Vaptans, 12
Vascular endothelial growth factor (VEGF), 8
Vilanterol, 9
Voxelotor, 13

X

Xenon, 7
Xipamide, 12
Xylometazoline, 15

Y

YK-11, 6

Z

Zeranol, 6
Zilpaterol, 6